A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

ClinicalTrials.gov ID: NCT07096843

Public ClinicalTrials.gov record NCT07096843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

Study identification

NCT ID: NCT07096843
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Climb Bio, Inc.; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Primary Membranous Nephropathy

Interventions

budoprutug Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 25, 2025 (Actual)
Primary completion: Oct 2027 (Estimated)
Completion: Oct 2027 (Estimated)
Last update posted: Oct 8, 2026

2025 – 2027

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
Climb Bio Investigative Site #110	Denver	Colorado	80220	Recruiting
Climb Bio Investigative Site #105	Orlando	Florida	32086	Recruiting
Climb Bio Investigative Site #108	Atlanta	Georgia	30342	Recruiting
Climb Bio Investigative Site #106	Indianapolis	Indiana	46268	Recruiting
Climb Bio Investigative Site #101	Clifton Park	New York	12065	Recruiting
Climb Bio Investigative Site #104	Sherman	Texas	75092	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07096843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 8, 2026 · Synced Nov 7, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07096843 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →